NO954722L - Peptid inhibitorer med urokinase reseptoraktivitet - Google Patents

Peptid inhibitorer med urokinase reseptoraktivitet

Info

Publication number
NO954722L
NO954722L NO954722A NO954722A NO954722L NO 954722 L NO954722 L NO 954722L NO 954722 A NO954722 A NO 954722A NO 954722 A NO954722 A NO 954722A NO 954722 L NO954722 L NO 954722L
Authority
NO
Norway
Prior art keywords
receptor activity
peptide inhibitors
urokinase receptor
urokinase
active
Prior art date
Application number
NO954722A
Other languages
English (en)
Other versions
NO954722D0 (no
Inventor
Steven Rosenberg
Michael V Doyle
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of NO954722L publication Critical patent/NO954722L/no
Publication of NO954722D0 publication Critical patent/NO954722D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6462—Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Effektive urokinase-type plasmlnogen aktlvator reseptorantagonister har sekvenser valgt fra gruppen AEPMPHSLNFSQYLWYT, AEWHPGLSFGSYLWSKT, AEHTYSSLWD- TYSPLAF, AESSLWTRYAWPSMPSY, AELDLWMRHYPLSFSNR, AEWSFYNLHLPEPOTIF, AETLFMDLWHDKHILLT, AEPLDLWS- LYSLPPLAM, AESLPTLTSILWGKESV, AESQTGTLNTLFWNTLR, AESSLWRIFSPSALMMS, AEPALLNWSFFFNPGLH, AEAWFLSNTM- KALSAKI, AEPTLWQLYQLYQFPLRLSG, AEISFSELMWLRSTPAF, AEWITSSPPLTQYLWGF, AEMHRSLWEWYVPNQSA, AEIKTDEKMGLWD- LYSM, AEILNFPLWHEPLWSTE, AELSEADLWITWFGMGS, AESV- OYSKLWKPNTTLA, AEPLSLYQKKTLRHFAN, AELPRTNPVTAVKNPSF, AEQLNRSIPDLQFSMFN OG AESHIKSLLDSSTWFLP eller aktive analoger eller aktive deler derav.
NO954722A 1993-05-28 1995-11-22 Peptid inhibitorer med urokinase reseptoraktivitet NO954722D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6151493A 1993-05-28 1993-05-28
PCT/US1994/005684 WO1994028014A2 (en) 1993-05-28 1994-05-19 Peptide inhibitors of urokinase receptor activity

Publications (2)

Publication Number Publication Date
NO954722L true NO954722L (no) 1995-11-22
NO954722D0 NO954722D0 (no) 1995-11-22

Family

ID=22036265

Family Applications (1)

Application Number Title Priority Date Filing Date
NO954722A NO954722D0 (no) 1993-05-28 1995-11-22 Peptid inhibitorer med urokinase reseptoraktivitet

Country Status (12)

Country Link
US (2) US5656726A (no)
EP (1) EP0745092B1 (no)
JP (2) JPH08510742A (no)
KR (1) KR960702846A (no)
AT (1) ATE182336T1 (no)
AU (1) AU682877B2 (no)
CA (1) CA2163741A1 (no)
DE (1) DE69419623T2 (no)
FI (1) FI955720A0 (no)
NO (1) NO954722D0 (no)
NZ (1) NZ267291A (no)
WO (1) WO1994028014A2 (no)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5519120A (en) * 1989-04-07 1996-05-21 Cancerforskningsfondet Af 1989 Urokinase-type plasminogen activator receptor antibodies
AU7137994A (en) 1993-06-01 1994-12-20 Chiron Corporation Expression of urokinase plasminogen activator inhibitors
US6248715B1 (en) 1993-06-01 2001-06-19 Chiron Corporation Method of treating a urokinase-type plasminogen activator-mediated disorder
US6030940A (en) * 1995-07-31 2000-02-29 Chiron Corporation Peptide analog inhibitors of urokinase receptor activity
WO1997005257A1 (en) * 1995-07-31 1997-02-13 Chiron Corporation Peptide analog inhibitors of urokinase receptor activity
US6010699A (en) * 1996-03-15 2000-01-04 Senju Pharmaceutical Co., Ltd. Method for controlling axial length of the eye
US20040204348A1 (en) * 1996-11-12 2004-10-14 The Angstrom Pharmaceuticals, Inc. Cyclic peptide ligands that target urokinase plasminogen activator receptor
US6277818B1 (en) * 1998-10-29 2001-08-21 Angstrom Pharmaceuticals, Inc. Cyclic peptide ligands that target urokinase plasminogen activator receptor
US5942492A (en) * 1996-11-12 1999-08-24 Angstrom Pharmaceuticals, Inc. Cyclic peptides that bind to urokinase-type plasminogen activator receptor
ES2224378T3 (es) * 1997-03-20 2005-03-01 Fondazione Centro San Raffaele Del Monte Tabor Peptidos mimetizadores de upar.
US6794358B1 (en) * 1997-03-28 2004-09-21 Brigham And Women's Hospital Peptide ligands of the urokinase receptor
US5994309A (en) 1997-07-25 1999-11-30 Angstrom Pharmaceuticals, Inc. Anti-invasive and anti-angiogenic compositions and methods
US6291514B1 (en) 1998-02-09 2001-09-18 3-Dimensional Pharmaceuticals, Inc. Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors
EP1142570A4 (en) 1998-10-02 2003-01-15 Santen Pharmaceutical Co Ltd ANGIOGENESE INHIBITORS
GB0002366D0 (en) * 2000-02-03 2000-03-22 Astrazeneca Uk Ltd Diagnostic method
US7566765B2 (en) * 2000-03-06 2009-07-28 Rigel Pharmaceuticals, Inc. Heterocyclic compounds containing a nine-membered carbon-nitrogen ring
DE60142899D1 (de) * 2000-06-20 2010-10-07 Dainippon Sumitomo Pharma Co Verbindungen für den transfer von oligonukleotiden
US6649597B1 (en) 2000-06-22 2003-11-18 The University Of Iowa Research Foundation Targeting vector to the urokinase plasminogen activator receptor
EP1407787B1 (en) * 2001-06-20 2009-04-29 Dainippon Sumitomo Pharma Co., Ltd. Method of promoting nucleic acid transfer
US6908899B2 (en) * 2001-08-17 2005-06-21 U.S. Dept. Of Veterans Affairs Pro-inflammatory fibrinopeptide
CA2468192A1 (en) * 2001-11-26 2003-06-05 Trustees Of Tufts College Peptidomimetic inhibitors of post-proline cleaving enzymes
AU2002358158A1 (en) * 2001-12-19 2003-06-30 D. Collen Research Foundation Use of urokinase receptor antagonists to modulate ischemiareperfusion injury
EP1696034A4 (en) * 2003-12-19 2006-12-27 Dainippon Sumitomo Pharma Co NUCLEIC ACID TRANSFER METHOD
US20090062184A1 (en) * 2005-03-24 2009-03-05 Dainippon Sumitomo Pharma Co., Ltd. Fine particulate preparation comprising complex of nucleic acid molecule and collagen
TW200813091A (en) * 2006-04-10 2008-03-16 Amgen Fremont Inc Targeted binding agents directed to uPAR and uses thereof
JP6861803B2 (ja) 2016-09-15 2021-04-21 ラブサイト インコーポレイテッド ソノポレーションを使用した生物学的細胞の高効率トランスフェクション
MA50363A (fr) 2017-10-12 2020-08-19 Vaxcyte Inc Vaccin contre la parodontite et compositions associées et procédé d'utilisation
AU2018374058A1 (en) 2017-11-22 2020-06-18 Dh Technologies Development Pte. Ltd. System and method for the acoustic loading of an analytical instrument using a continuous flow sampling probe
US10871430B2 (en) 2018-03-03 2020-12-22 Labcyte Inc. System and method for extracting a target moiety from a sample using acoustic droplet ejection
EA202192401A1 (ru) 2019-04-02 2022-03-30 Ваксайт, Инк. Оптимизированный бесклеточный синтез плазмидного антигена инвазии в и родственные композиции и способы применения

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4631270A (en) * 1978-11-20 1986-12-23 Research Corporation Therapeutically useful pseudopeptides, compositions containing the same and methods of preparation and use
US5519120A (en) * 1989-04-07 1996-05-21 Cancerforskningsfondet Af 1989 Urokinase-type plasminogen activator receptor antibodies
DK182289D0 (da) * 1989-04-14 1989-04-14 Francesco Blasi Modifikation af proteiner
US5039791A (en) * 1989-11-06 1991-08-13 Monsanto Company Peptide fragments of tissue plasminogen activator
GB2246779B (en) * 1990-08-03 1994-08-17 Delta Biotechnology Ltd Tumour-associated protease inhibitors targeted to tumour cells
JPH07501524A (ja) * 1991-11-18 1995-02-16 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン ｕＰＡ−Ｒの検出・分離方法及びｕＰＡのｕＰＡ−Ｒへの結合阻止方法
US5340833A (en) * 1992-05-01 1994-08-23 Eisai Co., Ltd. Urokinase inhibitors

Also Published As

Publication number Publication date
FI955720A (fi) 1995-11-27
JPH08510742A (ja) 1996-11-12
CA2163741A1 (en) 1994-12-08
NO954722D0 (no) 1995-11-22
EP0745092B1 (en) 1999-07-21
DE69419623T2 (de) 1999-12-02
JPH11240897A (ja) 1999-09-07
AU682877B2 (en) 1997-10-23
WO1994028014A3 (en) 1995-01-26
EP0745092A1 (en) 1996-12-04
NZ267291A (en) 1997-09-22
WO1994028014A2 (en) 1994-12-08
US5679782A (en) 1997-10-21
ATE182336T1 (de) 1999-08-15
KR960702846A (ko) 1996-05-23
US5656726A (en) 1997-08-12
FI955720A0 (fi) 1995-11-27
DE69419623D1 (de) 1999-08-26
AU6954294A (en) 1994-12-20

Similar Documents

Publication Publication Date Title
NO954722L (no) Peptid inhibitorer med urokinase reseptoraktivitet
FI953378A (fi) Sytokiiniä pidättävät aineet
HUP0300246A2 (en) Delivery system
DE69012888D1 (de) Plasminogenaktivator.
ES2196031T3 (es) Derivados peptidicos terapeutico.
DK1091975T3 (da) Ny cyclosporin med forbedret aktivitetsprofil
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
ATE277943T1 (de) Trypsininhibitoren
DE69625506D1 (de) Schwefelsubstituierte peptide als inhibitoren für metalloproteinasen und der tnf-freisetzung
DE69432608D1 (de) Expression von inhibitoren vom plasminogenaktivator vom urokinasetyp
ES2088128T3 (es) Aminosulfonilureas inhibidoras de acat.
HUT70579A (en) Bifunctional urocinase-variants having improved fibrinolytic properties and thrombin-inhibiting activity
OA09448A (fr) Dérivés de cyclopeptides, utilisables comme inhibiteurs sélectifs, vis-à-vis de protéases à sérine active.
EA200001127A1 (ru) Бактериальные феромоны и их использование
ATE57526T1 (de) P-acylaminobenzamide.
ITBO930092V0 (it) perfezionamento ad un elettrodo ad ancoraggio attivo per elettroca- teteri.
ATE89828T1 (de) Octapeptide als hemmer myristoylierender enzyme.